

Single technology appraisal (STA)

Ibrutinib for treating Waldenstrom's macroglobulinaemia

Cancer Drugs Fund - Glossary of terms

Term	Explanation
Commercial access agreement	The standard way for pharmaceutical companies to make cancer drugs cost effective for the NHS either when they are recommended by NICE for entry into the Cancer Drugs Fund or if they were a transition drug in July 2016 and undergoing appraisal by NICE as a transition drug for exiting from the Cancer Drugs Fund. Each agreement is approved by NHS England.
Patient access scheme	The standard way for pharmaceutical companies to make cancer drugs cost effective for the NHS when they are routinely commissioned. Each scheme is approved by the Department of Health. Patient access schemes are part of the Pharmaceutical Price Regulation Scheme (2014)
Managed access agreement	A Cancer Drugs Fund managed access agreement consists of two components: <ul style="list-style-type: none">· The first is a data collection arrangement, which sets out data that will be collected during the 'managed access' period to resolve clinical uncertainty· The second is a commercial access agreement that determines how much the NHS will pay for the treatment during the managed access period. This is normally a commercial access agreement that is managed by NHS England. However, if appropriate, a Department of Health-approved patient access scheme can also be used.